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Abstract 
Review on eIF4B, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: EIF-4B, PRO1843 
HGNC (Hugo): EIF4B 
Location: 12q13.13 
DNA/RNA 
Description 
The eIF4B gene codes for EIF4B protein. eIF4B 
gene is 69.15 kb in length and is composed of 15 
exons (Figure 1). 
Transcription 
eIF4B mRNA is ubiquitously expressed, however, 
regulation of eIF4B transcription has not been  
 
 
studied in detail. 
Protein 
Description 
eIF4B is a 79kDA protein composed of 611 
residues. Many sites of phosphorylation have been 
found for this protein using proteomics tools, 
including 29 Ser, 13 Thr and 1 Tyr (Prasad et al., 
2009). Among them, two have been validated by 
further studies. The best studied phosphorylation 
site is Ser422 by p70/S6kinase in response to 
mTOR pathway (Holz et al., 2005). Ser422 can also 
be phosphorylated by p90 (RSK) and PKB 
(Shahbazian et al., 2006; van Gorp et al., 2009). 
Ser406 phosphorylation is cell cycle dependent and 
under control of mTOR and MAP kinase pathways 
(van Gorp et al., 2009). Ser406 is a target of Pim 
kinases (Yang et al., 2013). Finally, eIF4B is 
cleaved by caspase 3 after Asp45 during apoptosis 
(Bushell et al., 2001) (Figure 2). 
 
 
Figure 1: Schematic representation of eIF4B gene, which is composed of 15 exons shown in blue. 
EIF4B (eukaryotic translation initiation factor 4B) Sbarrato T, et al. 
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Figure 2: Schematic representation of eIF4B protein. The numbers refer to amino acids flanking the functional domains. 
Ser406 and Ser422 that can be phosphorylated by several kinases are indicated. 
 
 
 
Figure 3: Initiation of translation. 
EIF4B (eukaryotic translation initiation factor 4B) Sbarrato T, et al. 
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Figure 4: Two possible models for eIF4B position in the initiation complex during scanning of 5'UTR. 
 
Expression 
The protein is reported to be expressed in most 
tissues, excluding liver, smooth muscle or soft 
tissues (Uhlen et al., 2010). Given the crucial role 
played by this protein in the cell, it is expected to be 
expressed ubiquitously albeit probably to different 
levels throughout different tissues. 
Localisation 
eIF4B has a cytoplasmic localisation. 
Function 
eIF4B is an RNA binding protein involved in the 
regulation of the initiation stage of protein 
synthesis. This protein is critical for the recruitment 
of the mRNA to the ribosome. It helps unwind 
secondary structures in the mRNA to allow 
ribosome scanning, via enhancing both ATPase and 
helicase activities of eIF4A. 
Translation of an mRNA initiates with the binding 
of eukaryotic initiation factor complex eIF4F 
comprised of eIF4E, eIF4G and eIF4A (Pestova and 
Kolupaeva, 2002) (Figure 3): 
- eIF4E interacts directly with the cap of the mRNA 
and helps recruit the machinery to the 5'end of the 
mRNA. 
- eIF4G protein provides a scaffold, bridging 
interactions between eIF4A, eIF4E, eIF3, PABP 
and RNA. 
- Secondary structures in the mRNA that can be 
detrimental to the binding/scanning of the ribosome 
are unwound by the helicase eIF4A and its 
cofactors eIF4B and eIF4H (Grifo et al., 1983; 
Lawson et al., 1989; Rozen et al., 1990). 
The binding of this eIF4F complex allows for the 
circularisation of the mRNA and the subsequent 
recruitment of the 43S pre-initiation complex (PIC) 
composed of the small ribosomal subunit (40S), the 
ternary complex (eIF2/met-tRNA/GTP) and several 
initiation factors (eIF1, eIF1A, eIF3 and eIF5) (Deo 
et al., 1999; Imataka et al., 1998; Lamphear et al., 
1995; Wells et al., 1998). This complex will then 
scan the untranslated region (UTR) of the mRNA 
until a start codon is recognised (Kozak, 2002). 
eIF4B acts at different levels to stimulate 
translation initiation: 1) by enhancing the ATPase 
and helicase activities of eIF4A and 2) by 
facilitating the recruitment of the 43S PIC. 
1) Role of eIF4B in the stimulation of eIF4A 
Although the precise mechanisms of action of 
eIF4B on the enhanced helicase activity of eIF4F 
are not fully understood, knockdown/aberrant 
expression of eIF4B in mammalian cells led to the 
reduction/stimulation in translation of mRNAs 
containing highly structured 5'UTRs (Horvilleur et 
al., 2013; Shahbazian et al., 2010). Additionally, 
the ATPase and helicase activity of free eIF4A was 
shown to be significantly slower than the rates of 
translation initiation or the rates of scanning of the 
PIC (Grifo et al., 1984; Pause et al., 1994; Richter-
Cook et al., 1998). 
Consequently, one can envisage that eIF4B can 
help in the substrate (ATP and RNA) recognition 
by eIF4A. As such, eIF4B can modulate the affinity 
for ATP and RNA by inducing conformational 
changes in eIF4A (Bi et al., 2000; Marintchev et al., 
2009; Methot et al., 1994; Nielsen et al., 2011; 
Rogers Jr. et al., 2001; Rozovsky et al., 2008). 
Additionally, eIF4B can enhance the efficiency of 
this process by coupling the ATP hydrolysis to 
duplex unwinding to avoid redundant, energy-
consuming events (Ozes et al., 2011). In a manner 
similar to other single-stranded DNA binding 
proteins that associate with helicases, one possible 
mode of action for eIF4B is to stabilize newly 
unwound single-stranded RNA. In support of this, a 
direct interaction between eIF4A and eIF4B in the 
presence of RNA and an ATP analog have been 
established via the C terminal region of eIF4B 
(Nielsen et al., 2011; Rozovsky et al., 2008). 
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Figure 5: mTOR and MEK/ERK/MAP kinase pathways converge on eIF4B. 
 
2) Role of eIF4B in the recruitment of 43S PIC 
to mRNAs 
Through its various domains, eIF4B is now known 
to promote the association of the various players in 
the recruitment of the 43S PIC to the mRNA. The C 
terminal RNA binding domain of eIF4B enables its 
binding to mRNA whereas the RRM motif triggers 
interaction with the rRNA from the 43S PIC 
(Methot et al., 1996a; Naranda et al., 1994). The 
latter is thought to anchor the helicase eIF4A to the 
scanning ribosome (Methot et al., 1996a). 
Importantly, mammalian eIF4B dimerises and binds 
to eIF3a via its DRYG repeats, thus providing a 
main link between the eIF4F-loaded mRNA and the 
43S PIC (Methot et al., 1996b). 
These results provide evidence that eIF4B 
participates in recruitment and assembly of the PIC 
on mRNAs. Critically, recent findings have now 
shown that interactions involving eIF4B via its 
different domains are essential for the effective 
assembly and efficient scanning of the 43S PIC. 
Yeast eIF4B together with eIF4F and eIF3 
decreased the dependency on high concentrations of 
eIF4A for the rapid assembly and recruitment of the 
43S PIC on endogenous short leader mRNAs 
(Mitchell et al., 2010; Walker et al., 2013), thus 
eIF4B can mediate an enhancing effect on the PIC 
recruitment to an mRNA. 
The spatial positioning of eIF4B on the scanning 
ribosome is poorly understood. The helicase 
complex eIF4A/eIF4B could be located near the 
mRNA exit channel (i.e. 5'/behind the scanning 
PIC) or alternatively at the mRNA entry channel 
(i.e. 3'/in front of the scanning PIC) (Figure 4). To 
support the former hypothesis, a Brownian ratchet 
model was proposed in which eIF4F is located near 
the exit channel of the PIC (Spirin, 2009).  
In this model, eIF4A-unwound and eIF4B-captured 
single-stranded RNA would be scanned by 
diffusion by the PIC. Contradictory, new evidence 
have shown that yeast eIF4B mapped to the head of 
the PIC near the entry channel (Walker et al., 
2013). In such a case, the eIF4F complex would be 
recruited to the cap and would be located at the 
forefront of the PIC, thus allowing efficient 
unwinding and scanning (Marintchev et al., 2009). 
New experimental approaches, including structures 
of the human ribosome associated with factors, 
should be able to shed some light on the matter in 
the future. 
Homology 
eIF4B is one of the least conserved initiation factors 
in terms of sequence homology (Cheng and Gallie, 
2006), however, its function is conserved and 
eIF4B homologues can be found across all  
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eukaryotic species. In addition to the human eIF4B, 
one of the most studied eIF4B homologs is the 
yeast protein, TIF3 (Altmann et al., 1993). eIF4H is 
a 23kDa paralog of eIF4B showing homology to the 
RRM RNA binding domain. eIF4H stimulates 
eIF4A helicase activity in a similar way to eIF4B. 
Implicated in 
General role in cancer 
Note 
eIF4B expression and phosphorylation are de-
regulated in many cancers. In particular, Ser422 
phosphorylation is at the crossroad of two major 
pathways in oncogenesis: MAP kinases and 
AKT/mTOR pathway (Shahbazian et al., 2006) 
(Figure 5). In response to these signalling 
pathways, eIF4B activates both global translation, 
driving faster proliferation, and overexpression of 
specific oncoproteins such as MYC or BCL2 
(Shahbazian et al., 2010). Activation of eIF4B and 
subsequent c-MYC induction is involved in arsenic-
induced transformation in mouse epithelial cells 
(Zhang et al., 2011). Moreover, binding of 14-3-3 
sigma tumour suppressor to eIF4B in late mitosis 
regulates translation indicating direct involvement 
of eIF4B in regulation of cell cycle (Wilker et al., 
2007). Finally, eIF4B is cleaved by a caspase 
dependent mechanism upon activation of tumour 
necrosis factor pathway, suggesting a role in 
preventing apoptosis (Jeffrey et al., 2002). 
Nasopharyngeal carcinoma (NPC) 
Note 
Although not mutated, p53 is known to be up-
regulated in NPC. In a proteomic study, eIF4B was 
shown to be down-regulated following p53 
knockdown in a NPC cell line (Sun et al., 2007). 
T-cell lymphoblastic 
leukemia/lymphoma 
Note 
eIF4B mRNA was found to be up-regulated in a 
genome wide study comparing mouse model of 
thymic tumours (lymphoblastic leukaemia 
precursor) to untransformed thymus (Lin and 
Aplan, 2007). 
Gastric cancer 
Note 
A microarray study found eIF4B mRNA to be up-
regulated in a panel of 22 patients after they became 
resistant to combined cisplatin and fludarabine 
treatment (Kim et al., 2011). 
Non-small cell lung cancer (NSCLC) 
Note 
Chromosomal aberrations in 12q13 region are  
frequent in NSCLC, where there can be either loss 
of heterozygocity or amplification, sometimes 
coupled with unbalanced translocation.  
eIF4B expression is significantly higher in NSCLC 
tumours showing this kind of alteration (Liang et 
al., 2013).  
Synergistic effect of mTOR and MEK inhibitors in 
NSCLC cell lines is correlated with significant 
decrease in eIF4B phosphorylation (Zou et al., 
2012). 
Oral squamous cell carcinoma 
Note 
Activation of Laminin γ2 by eIF4B is found in pre-
malignant oral dysplasia, where eIF4B is activated 
by ERK/MAP kinase pathway (Degen et al., 2012). 
Laminin γ2 levels remain high in oral squamous 
cell carcinoma, although eIF4B has not been 
studied in this context. 
Prostatic cancer 
Note 
In Prostatic carcinoma, eIF4B phosphorylation by 
Pim2 leads to resistance to apoptosis (Ren et al., 
2013). 
Lymphangioleiomyomatosis 
Note 
eIF4B phosphorylation increased following 
activation of mTOR pathway in 
lymphangioleiomyomatosis (Gu et al., 2013). 
Diffuse large B-cell lymphoma 
(DLBCL) 
Note 
eIF4B is up-regulated following activation of 
mTOR pathway in DLBCL and, in turn, activates 
translation of proteins involved in DNA repair and 
inhibition of apoptosis.  
Elevated eIF4B level was shown to be poor 
prognosis in DLBCL (Horvilleur et al., 2013). 
Various cancers 
Note 
Finally, amplification, duplication and deletion of 
12q13 have been described in different cancers 
including sarcoma, glioma, bladder carcinoma or 
anaplastic lymphoma without direct involvement of 
eIF4B. 
To be noted 
Doctors Thomas Sbarrato and Emilie Horvilleur 
contributed equally to this work. 
References 
Grifo JA, Tahara SM, Morgan MA, Shatkin AJ, Merrick 
WC. New initiation factor activity required for globin mRNA 
translation. J Biol Chem. 1983 May 10;258(9):5804-10 
EIF4B (eukaryotic translation initiation factor 4B) Sbarrato T, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 19(1) 9 
Grifo JA, Abramson RD, Satler CA, Merrick WC. RNA-
stimulated ATPase activity of eukaryotic initiation factors. J 
Biol Chem. 1984 Jul 10;259(13):8648-54 
Lawson TG, Lee KA, Maimone MM, Abramson RD, Dever 
TE, Merrick WC, Thach RE. Dissociation of double-
stranded polynucleotide helical structures by eukaryotic 
initiation factors, as revealed by a novel assay. 
Biochemistry. 1989 May 30;28(11):4729-34 
Rozen F, Edery I, Meerovitch K, Dever TE, Merrick WC, 
Sonenberg N. Bidirectional RNA helicase activity of 
eucaryotic translation initiation factors 4A and 4F. Mol Cell 
Biol. 1990 Mar;10(3):1134-44 
Altmann M, Müller PP, Wittmer B, Ruchti F, Lanker S, 
Trachsel H. A Saccharomyces cerevisiae homologue of 
mammalian translation initiation factor 4B contributes to 
RNA helicase activity. EMBO J. 1993 Oct;12(10):3997-
4003 
Méthot N, Pause A, Hershey JW, Sonenberg N. The 
translation initiation factor eIF-4B contains an RNA-binding 
region that is distinct and independent from its 
ribonucleoprotein consensus sequence. Mol Cell Biol. 
1994 Apr;14(4):2307-16 
Naranda T, Strong WB, Menaya J, Fabbri BJ, Hershey JW. 
Two structural domains of initiation factor eIF-4B are 
involved in binding to RNA. J Biol Chem. 1994 May 
20;269(20):14465-72 
Pause A, Méthot N, Svitkin Y, Merrick WC, Sonenberg N. 
Dominant negative mutants of mammalian translation 
initiation factor eIF-4A define a critical role for eIF-4F in 
cap-dependent and cap-independent initiation of 
translation. EMBO J. 1994 Mar 1;13(5):1205-15 
Lamphear BJ, Kirchweger R, Skern T, Rhoads RE. 
Mapping of functional domains in eukaryotic protein 
synthesis initiation factor 4G (eIF4G) with picornaviral 
proteases. Implications for cap-dependent and cap-
independent translational initiation. J Biol Chem. 1995 Sep 
15;270(37):21975-83 
Methot N, Pickett G, Keene JD, Sonenberg N. In vitro RNA 
selection identifies RNA ligands that specifically bind to 
eukaryotic translation initiation factor 4B: the role of the 
RNA remotif. RNA. 1996a Jan;2(1):38-50 
Méthot N, Song MS, Sonenberg N. A region rich in 
aspartic acid, arginine, tyrosine, and glycine (DRYG) 
mediates eukaryotic initiation factor 4B (eIF4B) self-
association and interaction with eIF3. Mol Cell Biol. 1996b 
Oct;16(10):5328-34 
Imataka H, Gradi A, Sonenberg N. A newly identified N-
terminal amino acid sequence of human eIF4G binds 
poly(A)-binding protein and functions in poly(A)-dependent 
translation. EMBO J. 1998 Dec 15;17(24):7480-9 
Richter-Cook NJ, Dever TE, Hensold JO, Merrick WC. 
Purification and characterization of a new eukaryotic 
protein translation factor. Eukaryotic initiation factor 4H. J 
Biol Chem. 1998 Mar 27;273(13):7579-87 
Wells SE, Hillner PE, Vale RD, Sachs AB. Circularization 
of mRNA by eukaryotic translation initiation factors. Mol 
Cell. 1998 Jul;2(1):135-40 
Deo RC, Bonanno JB, Sonenberg N, Burley SK. 
Recognition of polyadenylate RNA by the poly(A)-binding 
protein. Cell. 1999 Sep 17;98(6):835-45 
Bi X, Ren J, Goss DJ. Wheat germ translation initiation 
factor eIF4B affects eIF4A and eIFiso4F helicase activity 
by increasing the ATP binding affinity of eIF4A. 
Biochemistry. 2000 May 16;39(19):5758-65 
Bushell M, Wood W, Carpenter G, Pain VM, Morley SJ, 
Clemens MJ. Disruption of the interaction of mammalian 
protein synthesis eukaryotic initiation factor 4B with the 
poly(A)-binding protein by caspase- and viral protease-
mediated cleavages. J Biol Chem. 2001 Jun 
29;276(26):23922-8 
Rogers GW Jr, Richter NJ, Lima WF, Merrick WC. 
Modulation of the helicase activity of eIF4A by eIF4B, 
eIF4H, and eIF4F. J Biol Chem. 2001 Aug 
17;276(33):30914-22 
Jeffrey IW, Bushell M, Tilleray VJ, Morley S, Clemens MJ. 
Inhibition of protein synthesis in apoptosis: differential 
requirements by the tumor necrosis factor alpha family and 
a DNA-damaging agent for caspases and the double-
stranded RNA-dependent protein kinase. Cancer Res. 
2002 Apr 15;62(8):2272-80 
Kozak M. Pushing the limits of the scanning mechanism 
for initiation of translation. Gene. 2002 Oct 16;299(1-2):1-
34 
Pestova TV, Kolupaeva VG. The roles of individual 
eukaryotic translation initiation factors in ribosomal 
scanning and initiation codon selection. Genes Dev. 2002 
Nov 15;16(22):2906-22 
Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 
mediate assembly of the translation preinitiation complex 
through dynamic protein interchange and ordered 
phosphorylation events. Cell. 2005 Nov 18;123(4):569-80 
Cheng S, Gallie DR. Wheat eukaryotic initiation factor 4B 
organizes assembly of RNA and eIFiso4G, eIF4A, and 
poly(A)-binding protein. J Biol Chem. 2006 Aug 
25;281(34):24351-64 
Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, 
Taunton J, Hershey JW, Blenis J, Pende M, Sonenberg N. 
The mTOR/PI3K and MAPK pathways converge on eIF4B 
to control its phosphorylation and activity. EMBO J. 2006 
Jun 21;25(12):2781-91 
Lin YW, Aplan PD. Gene expression profiling of precursor 
T-cell lymphoblastic leukemia/lymphoma identifies 
oncogenic pathways that are potential therapeutic targets. 
Leukemia. 2007 Jun;21(6):1276-84 
Sun Y, Yi H, Zhang PF, Li MY, Li C, Li F, Peng F, Feng 
XP, Yang YX, Yang F, Xiao ZQ, Chen ZC. Identification of 
differential proteins in nasopharyngeal carcinoma cells with 
p53 silence by proteome analysis. FEBS Lett. 2007 Jan 
9;581(1):131-9 
Wilker EW, van Vugt MA, Artim SA, Huang PH, Petersen 
CP, Reinhardt HC, Feng Y, Sharp PA, Sonenberg N, 
White FM, Yaffe MB. 14-3-3sigma controls mitotic 
translation to facilitate cytokinesis. Nature. 2007 Mar 
15;446(7133):329-32 
Rozovsky N, Butterworth AC, Moore MJ. Interactions 
between eIF4AI and its accessory factors eIF4B and 
eIF4H. RNA. 2008 Oct;14(10):2136-48 
Marintchev A, Edmonds KA, Marintcheva B, Hendrickson 
E, Oberer M, Suzuki C, Herdy B, Sonenberg N, Wagner G. 
Topology and regulation of the human eIF4A/4G/4H 
helicase complex in translation initiation. Cell. 2009 Feb 
6;136(3):447-60 
Prasad TS, Kandasamy K, Pandey A. Human Protein 
Reference Database and Human Proteinpedia as 
discovery tools for systems biology. Methods Mol Biol. 
2009;577:67-79 
Spirin AS. How does a scanning ribosomal particle move 
along the 5'-untranslated region of eukaryotic mRNA? 
EIF4B (eukaryotic translation initiation factor 4B) Sbarrato T, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 19(1) 10 
Brownian Ratchet model. Biochemistry. 2009 Nov 
17;48(45):10688-92 
van Gorp AG, van der Vos KE, Brenkman AB, Bremer A, 
van den Broek N, Zwartkruis F, Hershey JW, Burgering 
BM, Calkhoven CF, Coffer PJ. AGC kinases regulate 
phosphorylation and activation of eukaryotic translation 
initiation factor 4B. Oncogene. 2009 Jan 8;28(1):95-106 
Mitchell SF, Walker SE, Algire MA, Park EH, Hinnebusch 
AG, Lorsch JR. The 5'-7-methylguanosine cap on 
eukaryotic mRNAs serves both to stimulate canonical 
translation initiation and to block an alternative pathway. 
Mol Cell. 2010 Sep 24;39(6):950-62 
Shahbazian D, Parsyan A, Petroulakis E, Topisirovic I, 
Martineau Y, Gibbs BF, Svitkin Y, Sonenberg N. Control of 
cell survival and proliferation by mammalian eukaryotic 
initiation factor 4B. Mol Cell Biol. 2010 Mar;30(6):1478-85 
Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson 
K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, 
Wernerus H, Björling L, Ponten F. Towards a knowledge-
based Human Protein Atlas. Nat Biotechnol. 2010 
Dec;28(12):1248-50 
Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Michalowski 
A, Green JE. A gene expression signature of acquired 
chemoresistance to cisplatin and fluorouracil combination 
chemotherapy in gastric cancer patients. PLoS One. 2011 
Feb 18;6(2):e16694 
Nielsen KH, Behrens MA, He Y, Oliveira CL, Jensen LS, 
Hoffmann SV, Pedersen JS, Andersen GR. Synergistic 
activation of eIF4A by eIF4B and eIF4G. Nucleic Acids 
Res. 2011 Apr;39(7):2678-89 
Özeş AR, Feoktistova K, Avanzino BC, Fraser CS. Duplex 
unwinding and ATPase activities of the DEAD-box helicase 
eIF4A are coupled by eIF4G and eIF4B. J Mol Biol. 2011 
Sep 30;412(4):674-87 
Zhang Y, Wang Q, Guo X, Miller R, Guo Y, Yang HS. 
Activation and up-regulation of translation initiation factor 
4B contribute to arsenic-induced transformation. Mol 
Carcinog. 2011 Jul;50(7):528-38 
Degen M, Natarajan E, Barron P, Widlund HR, Rheinwald 
JG. MAPK/ERK-dependent translation factor  
hyperactivation and dysregulated laminin γ2 expression in 
oral dysplasia and squamous cell carcinoma. Am J Pathol. 
2012 Jun;180(6):2462-78 
Zou ZQ, Zhang LN, Wang F, Bellenger J, Shen YZ, Zhang 
XH. The novel dual PI3K/mTOR inhibitor GDC-0941 
synergizes with the MEK inhibitor U0126 in non-small cell 
lung cancer cells. Mol Med Rep. 2012 Feb;5(2):503-8 
Gu X, Yu JJ, Ilter D, Blenis N, Henske EP, Blenis J. 
Integration of mTOR and estrogen-ERK2 signaling in 
lymphangioleiomyomatosis pathogenesis. Proc Natl Acad 
Sci U S A. 2013 Sep 10;110(37):14960-5 
Liang Y, Liu M, Wang P, Ding X, Cao Y. Analysis of 20 
genes at chromosome band 12q13: RACGAP1 and 
MCRS1 overexpression in nonsmall-cell lung cancer. 
Genes Chromosomes Cancer. 2013 Mar;52(3):305-15 
Ren K, Gou X, Xiao M, Wang M, Liu C, Tang Z, He W. The 
over-expression of Pim-2 promote the tumorigenesis of 
prostatic carcinoma through phosphorylating eIF4B. 
Prostate. 2013 Sep;73(13):1462-9 
Walker SE, Zhou F, Mitchell SF, Larson VS, Valasek L, 
Hinnebusch AG, Lorsch JR. Yeast eIF4B binds to the head 
of the 40S ribosomal subunit and promotes mRNA 
recruitment through its N-terminal and internal repeat 
domains. RNA. 2013 Feb;19(2):191-207 
Yang J, Wang J, Chen K, Guo G, Xi R, Rothman PB, 
Whitten D, Zhang L, Huang S, Chen JL. eIF4B 
phosphorylation by pim kinases plays a critical role in 
cellular transformation by Abl oncogenes. Cancer Res. 
2013 Aug 1;73(15):4898-908 
Horvilleur E, Sbarrato T, Hill K, Spriggs RV, Screen M, 
Goodrem PJ, Sawicka K, Chaplin LC, Touriol C, Packham 
G, Potter KN, Dirnhofer S, Tzankov A, Dyer MJ, Bushell M, 
MacFarlane M, Willis AE. A role for eukaryotic initiation 
factor 4B overexpression in the pathogenesis of diffuse 
large B-cell lymphoma. Leukemia. 2014 May;28(5):1092-
102 
This article should be referenced as such: 
Sbarrato T, Horvilleur E, Pöyry T, Willis AE. EIF4B 
(eukaryotic translation initiation factor 4B). Atlas Genet 
Cytogenet Oncol Haematol. 2015; 19(1):4-10. 
